- Home
- NERV vs GOVX Comparison
NERV vs GOVX Comparison
Compare NERV & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- GOVX
- Stock Information
- Founded
- NERV 2007
- GOVX 2001
- Country
- NERV United States
- GOVX United States
- Employees
- NERV N/A
- GOVX N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- GOVX Health Care
- Exchange
- NERV Nasdaq
- GOVX Nasdaq
- Market Cap
- NERV 14.6M
- GOVX 16.8M
- IPO Year
- NERV 2014
- GOVX N/A
- Fundamental
- Price
- NERV $2.83
- GOVX $0.58
- Analyst Decision
- NERV Hold
- GOVX Strong Buy
- Analyst Count
- NERV 1
- GOVX 3
- Target Price
- NERV $5.00
- GOVX $10.67
- AVG Volume (30 Days)
- NERV 639.5K
- GOVX 1.1M
- Earning Date
- NERV 11-04-2025
- GOVX 11-11-2025
- Dividend Yield
- NERV N/A
- GOVX N/A
- EPS Growth
- NERV N/A
- GOVX N/A
- EPS
- NERV 1.48
- GOVX N/A
- Revenue
- NERV N/A
- GOVX $6,143,044.00
- Revenue This Year
- NERV N/A
- GOVX N/A
- Revenue Next Year
- NERV N/A
- GOVX N/A
- P/E Ratio
- NERV $1.47
- GOVX N/A
- Revenue Growth
- NERV N/A
- GOVX 1943.07
- 52 Week Low
- NERV $1.15
- GOVX $0.43
- 52 Week High
- NERV $3.29
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- NERV 70.41
- GOVX 38.26
- Support Level
- NERV $2.06
- GOVX $0.54
- Resistance Level
- NERV $2.15
- GOVX $0.59
- Average True Range (ATR)
- NERV 0.11
- GOVX 0.04
- MACD
- NERV 0.02
- GOVX -0.00
- Stochastic Oscillator
- NERV 70.72
- GOVX 40.38
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.